Moxifloxacin

C. diff Risk

High

Oral Bioavailability

Excellent

Approximate Cost

Spectrum Of Activity

Dosing

400 mg IV/PO daily

No dose adjustment

General Information

Drug Monitoring

Monitor QTc in patients with increased risk

Adverse Effects

  •  QTc prolongation

  • Dysglycemia

  • CNS toxicity including confusion, psychosis

  • Tendinopathy and rupture

  • GI upset

  • Weakness exacerbation in myasthenia gravis

  • Rash

Major Interactions

QTc prolongation - Increased risk with other agents that prolong QTc

Divalent cations including Ca, Mg - decreased absorption

Warfarin - increased INR

Rifampin - decrease moxifloxacin levels

Additional Information

Low urinary drug levels - do not use to treat UTI.

May exacerbate muscle weakness in persons with myasthenia gravis. Avoid Use.

Pharmacology

Antimicrobial class: Fluoroquinolone

Pregnancy category: C